{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:16:51Z","timestamp":1785187011058,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770126"],"award-info":[{"award-number":["81770126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770161"],"award-info":[{"award-number":["81770161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800163"],"award-info":[{"award-number":["81800163"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejphar.2021.174633","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T02:00:15Z","timestamp":1637978415000},"page":"174633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K\/AKT pathway attenuation and Myc downregulation"],"prefix":"10.1016","volume":"913","author":[{"given":"Lihong","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174633_bib1","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00280-013-2326-3","article-title":"Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients","volume":"72","author":"Ahmed","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174633_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12032-019-1253-5","article-title":"Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia","volume":"36","author":"Alves","year":"2019","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejphar.2021.174633_bib3","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.174633_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/CAD.0000000000001028","article-title":"Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation","volume":"32","author":"Asari","year":"2021","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejphar.2021.174633_bib5","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jamacardio.2019.2306","article-title":"Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 Years or older: a secondary analysis of a randomized clinical trial","volume":"4","author":"Bach","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ejphar.2021.174633_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179558","article-title":"Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia","volume":"12","author":"Bandyopadhyay","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2021.174633_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.molcel.2016.02.019","article-title":"Mitochondria-judges and executioners of cell death sentences","volume":"61","author":"Bhola","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2021.174633_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","article-title":"Mitochondria as multifaceted regulators of cell death","volume":"21","author":"Bock","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2021.174633_bib10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2021.174633_bib11","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1073\/pnas.0900653106","article-title":"Charting the molecular network of the drug target Bcr-Abl","volume":"106","author":"Brehme","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2021.174633_bib12","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2021.174633_bib13","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.4049\/jimmunol.0903025","article-title":"PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes","volume":"184","author":"Chan","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2021.174633_bib14","first-page":"528","article-title":"Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death","volume":"28","author":"Chen","year":"2011","journal-title":"Med. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2021.174633_bib15","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejphar.2021.174633_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2021.174633_bib17","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2021.174633_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2021.174633_bib19","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2021.174633_bib20","article-title":"Epigenetic modifications of c-MYC: role in cancer cell reprogramming, progression and chemoresistance","author":"Fatma","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejphar.2021.174633_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.exphem.2014.02.006","article-title":"Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib","author":"Glodkowska-Mrowka","year":"2014","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejphar.2021.174633_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Hantschel","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejphar.2021.174633_bib23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejphar.2021.174633_bib24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2021.174633_bib25","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2021.174633_bib26","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1111\/bph.14781","article-title":"Mitochondrial protection by simvastatin against angiotensin II-mediated heart failure","volume":"176","author":"Hsieh","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174633_bib27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.12659\/MSM.908553","article-title":"Inhibition of Siah2 ubiquitin ligase by Vitamin K3 attenuates chronic myeloid leukemia chemo-resistance in hypoxic microenvironment","volume":"24","author":"Huang","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ejphar.2021.174633_bib28","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2021.174633_bib29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2021.174633_bib30","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1186\/s12885-019-6405-7","article-title":"SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial","volume":"19","author":"Jameson","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2021.174633_bib31","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2021.174633_bib32","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/leu.2009.49","article-title":"Bcr-Abl-mediated redox regulation of the PI3K\/AKT pathway","volume":"23","author":"Li","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2021.174633_bib33","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/beta-Catenin signaling, disease, and emerging therapeutic modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2021.174633_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/CAD.0b013e32835a0fbd","article-title":"Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells","volume":"24","author":"Oh","year":"2013","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejphar.2021.174633_bib35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1158\/1541-7786.MCR-13-0650","article-title":"PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD","volume":"12","author":"Pareja","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejphar.2021.174633_bib36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41556-020-0507-y","article-title":"Overcoming Wnt-beta-catenin dependent anticancer therapy resistance in leukaemia stem cells","volume":"22","author":"Perry","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejphar.2021.174633_bib37","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.7150\/thno.19884","article-title":"c-Myc is required for BRAF(V600E)-induced epigenetic silencing by H3K27me3 in tumorigenesis","volume":"7","author":"Qu","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2021.174633_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8723","article-title":"Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC\/BCL2 double-hit B cell lymphoma","volume":"10","author":"Rava","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2021.174633_bib39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2021.174633_bib40","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","article-title":"Dominant negative MYC blocks transformation by ABL oncogenes","volume":"70","author":"Sawyers","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2021.174633_bib41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2021.174633_bib42","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1111\/bph.13166","article-title":"Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of TGF-beta receptor III expression","volume":"172","author":"Sun","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174633_bib43","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-17-3107","article-title":"Deptor is a novel target of Wnt\/beta-catenin\/c-Myc and contributes to colorectal cancer cell growth","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2021.174633_bib44","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2021.174633_bib45","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1186624","article-title":"The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML","volume":"327","author":"Wang","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2021.174633_bib46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/CAD.0b013e32834a099c","article-title":"Methyl-beta-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and, combined with imatinib, produces a synergistic downregulation of ERK\/SPK1 signaling","volume":"23","author":"Yan","year":"2012","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejphar.2021.174633_bib47","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000158663","article-title":"In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells","volume":"54","author":"Yang","year":"2008","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejphar.2021.174633_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.canlet.2018.04.001","article-title":"Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer","volume":"426","author":"Yin","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2021.174633_bib49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.14715\/cmb\/2020.66.6.15","article-title":"Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K\/AKT signaling pathway","volume":"66","author":"Yuan","year":"2020","journal-title":"Cell. Mol. Biol. (Noisy-Le-Grand)"},{"key":"10.1016\/j.ejphar.2021.174633_bib50","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2021.174633_bib51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-020-00213-8","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct. Target Ther."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921007895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921007895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:55:29Z","timestamp":1757976929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921007895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":50,"alternative-id":["S0014299921007895"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174633","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K\/AKT pathway attenuation and Myc downregulation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174633"}}